Michael G. Grey - 29 May 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Reporting relationship: Director
Issuer ticker: MIRM
Reported as of: 29 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2025, 19:38:18 UTC
Prior SEC filing: 30 May 2025
Next SEC filing: 24 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Michael G. Grey filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 02 Jun 2025.

Key facts

This page summarizes Michael G. Grey's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Jun 2025, 19:38.

Change

Previous filing in this sequence was filed on 30 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001240122 Primary reporting owner

GREY MICHAEL G

Relationship: Director
Address: C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY
Signature: /s/ Judit Ryvkin, Attorney-in-Fact
Signature date: 02 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRM transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +6,268
Change %
Price: $0.000000
Shares after: 6,268
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,268
Exercise price: $44.00
Footnotes: F1

MIRM transaction Derivative

Deferred Stock Units

Award

Transaction value: $0
Shares: +3,977
Change %
Price: $0.000000
Shares after: 3,977
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,977
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting.

Footnote F2

Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.